Breast cancer Trials in Chiang Mai, Thailand
Conditions / Breast cancer / Chiang Mai, Thailand
Breast cancer has been the subject of sustained clinical investigation across multiple research sites.
19 total trials for this combination
Showing top 10 of 19 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | COMPLETED | PHASE3 |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | RECRUITING | PHASE3 |
| NCT00528567 | BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer | COMPLETED | PHASE3 |
| NCT06103864 | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | RECRUITING | — |
| NCT00863655 | Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole | COMPLETED | PHASE3 |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC | COMPLETED | PHASE3 |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | RECRUITING | PHASE1/PHASE2 |
| NCT05374512 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04191499 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | COMPLETED | PHASE3 |